351 related articles for article (PubMed ID: 28544785)
21. CXCR4 Ligands: The Next Big Hit?
Walenkamp AME; Lapa C; Herrmann K; Wester HJ
J Nucl Med; 2017 Sep; 58(Suppl 2):77S-82S. PubMed ID: 28864616
[TBL] [Abstract][Full Text] [Related]
22. Expression of CXCL12 and CXCR4 in pT3-stage gastric cancer does not correlate with peritoneal metastasis.
Tsuboi K; Kodera Y; Nakanishi H; Ito S; Mochizuki Y; Nakayama G; Koike M; Fujiwara M; Yamamura Y; Nakao A
Oncol Rep; 2008 Nov; 20(5):1117-23. PubMed ID: 18949410
[TBL] [Abstract][Full Text] [Related]
23. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
26. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
27. The CXCL12-CXCR4 Signaling Axis Plays a Key Role in Cancer Metastasis and is a Potential Target for Developing Novel Therapeutics against Metastatic Cancer.
Yang P; Hu Y; Zhou Q
Curr Med Chem; 2020; 27(33):5543-5561. PubMed ID: 31724498
[TBL] [Abstract][Full Text] [Related]
28. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.
Chong BF; Mohan C
Expert Opin Ther Targets; 2009 Oct; 13(10):1147-53. PubMed ID: 19670960
[TBL] [Abstract][Full Text] [Related]
29. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
30. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
Kim SY; Lee CH; Midura BV; Yeung C; Mendoza A; Hong SH; Ren L; Wong D; Korz W; Merzouk A; Salari H; Zhang H; Hwang ST; Khanna C; Helman LJ
Clin Exp Metastasis; 2008; 25(3):201-11. PubMed ID: 18071913
[TBL] [Abstract][Full Text] [Related]
32. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.
Mousavi A
Immunol Lett; 2020 Jan; 217():91-115. PubMed ID: 31747563
[TBL] [Abstract][Full Text] [Related]
33. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
34. Retinoblastoma tumor suppressor gene 1 enhances 5-Fluorouracil chemosensitivity through SDF-1/CXCR4 axis by regulating autophagy in gastric cancer.
Tang H; Long Q; Zhuang K; Han K; Zhang X; Guo H; Lu X
Pathol Res Pract; 2021 Aug; 224():153532. PubMed ID: 34214844
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
36. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
Katsura M; Shoji F; Okamoto T; Shimamatsu S; Hirai F; Toyokawa G; Morodomi Y; Tagawa T; Oda Y; Maehara Y
Cancer Sci; 2018 Jan; 109(1):154-165. PubMed ID: 29032612
[TBL] [Abstract][Full Text] [Related]
37. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis.
Tanegashima K; Suzuki K; Nakayama Y; Tsuji K; Shigenaga A; Otaka A; Hara T
FEBS Lett; 2013 Jun; 587(12):1731-5. PubMed ID: 23669361
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
40. Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.
Albert S; Riveiro ME; Halimi C; Hourseau M; Couvelard A; Serova M; Barry B; Raymond E; Faivre S
Head Neck; 2013 Dec; 35(12):1819-28. PubMed ID: 23468253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
